We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Oracle Corporation (ORCL).
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.
Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
pharmaceuticals: Archive
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
by Zacks Equity Research
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
ACETNegative Net Change ADMANegative Net Change FGENPositive Net Change AQSTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
BMYNegative Net Change JNJNegative Net Change ADMANegative Net Change TSVTPositive Net Change
biotechnology biotechs pharmaceuticals
Take the Zacks Approach to Beat the Market: NVIDIA, Fastenal, HORIBA in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
NVOPositive Net Change FASTPositive Net Change ETNPositive Net Change NVDAPositive Net Change TSCONegative Net Change HRLPositive Net Change UTIPositive Net Change POWLNegative Net Change HRIBFNo Net Change BLWYYNo Net Change UBERNegative Net Change
internet pharmaceuticals semiconductor
Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron
by Zacks Equity Research
AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron have been highlighted in this Screen of The Week article.
TXTPositive Net Change EMEPositive Net Change KALUNegative Net Change APPPositive Net Change COLLPositive Net Change
pharmaceuticals
J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use
by Zacks Equity Research
J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.
GSKNegative Net Change JNJNegative Net Change VNDANegative Net Change ADMANegative Net Change
pharmaceuticals
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
by Zacks Equity Research
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
ACETNegative Net Change ADMANegative Net Change FGENPositive Net Change MIRMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
LLYPositive Net Change VKTXPositive Net Change MDGLPositive Net Change AKRONegative Net Change
biotechs pharmaceuticals
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
by Kinjel Shah
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
AZNNegative Net Change JNJNegative Net Change PFENegative Net Change NVOPositive Net Change LLYPositive Net Change
pharmaceuticals
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
GSKNegative Net Change BMYNegative Net Change JNJNegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
by Zacks Equity Research
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
GSKNegative Net Change GERNNegative Net Change ADMANegative Net Change FGENPositive Net Change
biotechnology medical pharmaceuticals
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
by Zacks Equity Research
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
REGNNegative Net Change MRNAPositive Net Change RGLSPositive Net Change ACADPositive Net Change AMLXNegative Net Change
biotechnology biotechs pharmaceuticals
Amazon (AMZN) Boosts Pharmacy Efforts With Lilly's Partnership
by Zacks Equity Research
Amazon (AMZN) teams up with Lilly to deliver drug prescriptions that are sent to the latter's direct-to-consumer service, LillyDirect.
AMZNPositive Net Change LLYPositive Net Change EBAYNegative Net Change KRPositive Net Change
pharmaceuticals retail
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
by Zacks Equity Research
AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
AZNNegative Net Change ACETNegative Net Change ADMANegative Net Change FGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
by Zacks Equity Research
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change ADMANegative Net Change
biotechs medical pharmaceuticals
Lilly (LLY) Partners Amazon to Deliver Drugs Like Zepbound
by Zacks Equity Research
Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.
AMZNPositive Net Change NVOPositive Net Change LLYPositive Net Change
pharmaceuticals
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
by Zacks Equity Research
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
ACETNegative Net Change PCRXNegative Net Change ADMANegative Net Change FGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Stock Reports for UnitedHealth, Johnson & Johnson & Oracle
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Oracle Corporation (ORCL).
WFCPositive Net Change CATPositive Net Change UNHNegative Net Change JNJNegative Net Change ORCLPositive Net Change ADBEPositive Net Change
computers medical pharmaceuticals
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
by Zacks Equity Research
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.
REGNNegative Net Change ADMANegative Net Change FGENPositive Net Change NAMSPositive Net Change
biotechnology biotechs pharmaceuticals
Inflation Remains Sticky in February: 5 Safe Picks
by Nalak Das
We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.
GSKNegative Net Change TMPositive Net Change TAPNegative Net Change TSNNegative Net Change BAHNegative Net Change
auto-tires-trucks business-services consumer-staples pharmaceuticals
Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study
by Zacks Equity Research
Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.
GSKNegative Net Change PFENegative Net Change VNDANegative Net Change ADMANegative Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Novo Nordisk, Tesla, Airbnb, ONEOK and CDW
by Zacks Equity Research
Novo Nordisk, Tesla, Airbnb, ONEOK and CDW are part of the Zacks top Analyst Blog.
NVOPositive Net Change OKEPositive Net Change TSLAPositive Net Change CDWNegative Net Change ABNBPositive Net Change
auto-tires-trucks computers internet-content oil-energy pharmaceuticals
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
by Zacks Equity Research
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.
ACETNegative Net Change ADMANegative Net Change FGENPositive Net Change APLTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Top Research Reports for Novo Nordisk, Tesla & Airbnb
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Tesla, Inc. (TSLA) and Airbnb, Inc. (ABNB).
SLBPositive Net Change NVOPositive Net Change OKEPositive Net Change TSLAPositive Net Change CDWNegative Net Change ABNBPositive Net Change
auto-tires-trucks computers pharmaceuticals
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
by Zacks Equity Research
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
GSKNegative Net Change INCYNegative Net Change ADMANegative Net Change FGENPositive Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
REGNNegative Net Change SNYNegative Net Change ADMANegative Net Change FGENPositive Net Change
biotechnology biotechs pharmaceuticals